1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Singapore Pharmaceuticals and Healthcare Report Q4 2016

Singapore Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 104 pages

Includes 3 FREE quarterly updates

BMI View:

The delivery of healthcare in Singapore will continue to change as the country looks to deepenthe integration of technology with its medical sector. This will see a shift in the flow of patients seekingmedical services, their interaction with physicians and potentially the use of pharmaceuticals as mobileapplications play a greater role. Consequently, drugmakers will have to adapt their marketing strategies toaccount for these shifts in the patient journey to capture the commercial opportunities in the Singaporemarket.

Headline Expenditure Projections


- Pharmaceuticals: SGD1.1bn (USD798mn) in 2015 to SGD1.2bn (USD844mn) by 2016; +5.4% in localcurrency terms and 5.7% in USD terms. US dollar values upgraded in line with shifts in currency.

- Healthcare: SGD21.3bn (USD15.5bn) in 2015 to SGD23.5bn (USD17.2bn) by 2016; +10.5% in localcurrency terms and 10.8% in USD terms. US dollar values upgraded in line with currency changes.Risk/Reward IndexSingapore is ranked seventh out of 19 other Asia Pacific markets (scoring 60.9 out of a maximum 100) onBMI's Pharmaceutical Risk/Reward Index for Q416. The country's above average score on country rewards(scoring 17.1 out of 21.0) with the highest score for risk (27.8 out of 35) in the region is weighed down bythe limited industry rewards (16.0 out of 44.0) due to the country's small population.Latest Updates

- In May 2016, Mundipharma announced that it will be establishing a new SGD100mn (USD74mn) globalresearch and development (R&D) centre in the country. Slated to begin operations in January 2018, the facility will be the world's first betadine consumer health hub that combines R&D, manufacturing anddistribution into one. A key focus of the hub would be on finding new ways to combat infectiousdiseases.

Table Of Contents

Singapore Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Singapore 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Singapore 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 21
Singapore 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (Singapore 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Singapore 2014-2020) 27
Industry Risk/Reward Index 28
Asia Pacific Risk/Reward Index - Q4 2016 28
Singapore Risk/Reward Index 35
Rewards 35
Risks 35
Regulatory Review 36
Table: Regulatory Process Time Taken Under The CECA And Under The Abridged GDA 38
Intellectual Property Issues 39
Pricing And Reimbursement Regime 40
Market Overview 45
Healthcare Sector 45
Table: Health Funding Sources In Singapore (SGDmn) 49
Table: Change In Benefits 50
Table: Healthcare Resources (Singapore 2010-2015) 51
Table: Healthcare Activity (Singapore 2010-2015) 51
Table: Healthcare Personnel (Singapore 2010-2015) 52
Research and Development 52
Clinical Trials 54
Epidemiology 55
Table: Estimated Number Of New Cases Of Cancer In Singapore 57
Competitive Landscape 59
Research-Based Industry 59
Table: Multinational Pharmaceutical Firm Presence In Singapore 59
Table: Multinational Market Activity 60
Table: Leading Generic Drugmakers In Singapore 62
Pharmaceutical Distribution 63
Pharmaceutical Retail Sector 66
Company Profile 68
Baxter 68
GlaxoSmithKline 70
Haw Par 73
Merck and Co 76
MerLion 79
Novartis 82
Pfizer 85
Sanofi 88
Sci Gen 90
Demographic Forecast 93
Demographic Outlook 93
Table: Population Headline Indicators (Singapore 1990-2025) 94
Table: Key Population Ratios (Singapore 1990-2025) 94
Table: Urban/Rural Population and Life Expectancy (Singapore 1990-2025) 95
Table: Population By Age Group (Singapore 1990-2025) 95
Table: Population By Age Group % (Singapore 1990-2025) 96
Glossary 98
Methodology 100
Pharmaceutical Expenditure Forecast Model 100
Healthcare Expenditure Forecast Model 100
Notes On Methodology 101
Risk/Reward Index Methodology 102
Index Overview 103
Table: Pharmaceutical Risk/Reward Index Indicators 103
Indicator Weightings 104

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.